D003424DisordersC06.405.205.731.500C06.405.469.432.5001197290.615876Crohn Diseaseplugins:TwitterTwitterprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonPediatrics-Gastroenterology27.26440.00143984119research area of0.9830650.00935149593subject area forMedicine-Gastroenterologyhttps://rubinlab.uchicago.edu/Rubin Lab Sitehttps://www.uchicagomedicine.org/conditions-services/inflammatory-bowel-diseaseInflammatory Bowel Disease CenterIBDMDMedicineUniversity of Chicago37738465D'Haens G, Eberhardson M, Cabrijan Z, Danese S, van den Berg R, Löwenberg M, Fiorino G, Schuurman PR, Lind G, Almqvist P, Olofsson PS, Tracey KJ, Hanauer SB, Zitnik R, Chernoff D, Levine YAJournal of Crohn's & colitisNeuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.J Crohns Colitis2023-12-30T00:00:002023Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study.Joel R.Pekowx2diBLY1DO/RmHllZ0mg9mHvJoel R. Pekow41.78927490000000-87.601250000000001867Pekow, Joel R.Associate ProfessorRussell D.CohenRussell D. Cohen41.78927490000000-87.601250000000002354Cohen, Russell D.ProfessorDavid T.RubinDavid T. Rubin41.78927490000000-87.60125000000000256Rubin, David T.ProfessorStephenHanauerStephen B. Hanauer41.78927490000000-87.60125000000000660Hanauer, StephenEmeritus/EmeritaBarbaraKirschnerBarbara S. Kirschner41.78927490000000-87.60125000000000964Kirschner, BarbaraEmeritus/Emerita, Professor (CS)38104569Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI-1 Study GroupThe lancet. Gastroenterology & hepatologyEfficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146.Lancet Gastroenterol Hepatol2023-12-14T00:00:002023Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.38110655Kay J, Cross RK, Feldman SR, Park Y, Hanauer SBAdvances in therapyReview of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Adv Ther. 2024 Feb; 41(2):509-533.Adv Ther2023-12-19T00:00:002023Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases.38112840Miyatani Y, Choi D, Choi NK, Rubin DTDigestive diseases and sciencesDual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.Dig Dis Sci2023-12-19T00:00:002023Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.38153747Moir J, Hyman MJ, Wang J, Shah A, Maatouk C, Flores A, Skondra DInvestigative ophthalmology & visual scienceAssociations Between Autoimmune Disease and the Development of Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2023 Dec 01; 64(15):45.Invest Ophthalmol Vis Sci2023-12-01T00:00:002023Associations Between Autoimmune Disease and the Development of Age-Related Macular Degeneration.true1ProfessorProfessortrue1Emeritus/EmeritaEmeritus/Emeritatrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Emeritus/Emerita, Professor (CS)Emeritus/Emerita, Professor (CS)